Acute hepatitis C: In search of the optimal approach to cure

Hepatology

Volumn 43, Issue 2, 2006, Pages 221-224

  Craxì, Antonio ^a   Licata, Anna ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAN3 INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ACUTE HEPATITIS; CHRONIC HEPATITIS; CHRONICITY; CLINICAL TRIAL; DISEASE TRANSMISSION; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; INTRAVENOUS DRUG ABUSE; NEEDLESTICK INJURY; PRIORITY JOURNAL; SEROCONVERSION; SERODIAGNOSIS; SEXUAL TRANSMISSION; TREATMENT OUTCOME; TREATMENT REFUSAL; VIRUS TRANSMISSION;

ACUTE DISEASE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; PATIENT SELECTION;

EID: 33644607004     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21085     Document Type: Editorial

References (31)

1. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005;43:590-598.
2. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
3. Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, et al. Viral and host factors in early hepatitis C virus infection. HEPATOLOGY 2005;42:86-92.
4. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000 14;288:339-344.
5. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, Negro F. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-328.
6. Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, et al. Hepatitis C viral genotype influences the clinical outcome of patients with acute post-transfusion hepatitis C. J Med Virol 2001;65:505-509.
7. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004;73:387-391.
8. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
9. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
10. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005;42:646-651.
11. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. HEPATOLOGY 2003;37:60-64.
12. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
13. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C. When and how to treat acute hepatitis C? J Hepatol 2003;39:1056-1062.
14. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19(Jun 10-12):1-46.
15. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland. J Hepatol 2003;39(Suppl 1):S1-S235.
16. Zekry A, Patel K, McHutchison JG. Treatment of acute hepatitis C infection: more pieces of the puzzle? J Hepatol 2005;42:293-296.
17. Wedemeyer H, Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann C, et al. Early monotherapy with peginterferon alfa-2b for acute hepatitis C infection: The HEP-NET Acute-HCV-II Study. HEPATOLOGY 2006;43:250-256.
18. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. HEPATOLOGY 2001;34:395-403.
19. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann C, Berg T, et al. Relevance of adherence in the treatment of acute hepatitis C infection: final results of the German HEP-NET Acute Hepatitis C II Trial. HEPATOLOGY 2005;42(Suppl 1):647A.
20. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005;40:41-46.
21. Wedemeyer H, Jackel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. HEPATOLOGY 2004;39:1201-1203.
22. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003;35:104-113.
23. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. HEPATOLOGY 121 2004;39:1213-9.
24. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999;31(Suppl 1):189-192.
25. Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokaddem F, Wain E, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004;20:15-22.
26. Vyas K, Brassard DL, DeLorenzo MM, Sun Y, Grace MJ, Borden EC, et al. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interteron-alpha2b: gene modulatory and antigrowth effects in tumor cells. J Immunother 2003;26:202-211.
27. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005;42:329-333.
28. Talleri G, Cariti G, Gaiottino F, De Rosa F, De Blasi T, Audagnotto S, et al. Three months course of PEG IFN alfa 2b in acute HCV hepatitis [Abstract]. HEPATOLOGY 2004;40(Suppl 1):179A.
29. Rocca P, Bailly F, Chevallier M, Chevallier P, Zoulim F, Trepo C. Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients Gastroenterol Clin Biol 2003;27:294-299.
30. Pimstone NR, Pimstone D, Saicheur T, Powell J, Yu AS. "Wait-and-see": an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monotherapy. Ann Intern Med 2004;141:W91-W92.
31. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. HEPATOLOGY 2004;40:98-107.